NASDAQ$CMPS
COMPASS Pathways plc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2023 and provided a business update.
COMPASS Pathways reported a net loss of $24.2 million for the first quarter of 2023. The Phase 3 pivotal program for COMP360 is underway, and a CPT III code for in-person psychedelic therapy support has been accepted by the American Medical Association. The company's cash position as of March 31, 2023, was $117.1 million, with an additional $26.9 million raised through an ATM facility to date in the second quarter.
- COMP360 Phase 3 pivotal program is underway with patients being treated in both trials.
- CPT® III code for in-person psychedelic therapy support accepted by the American Medical Association.
- Cash position at 31 March 2023 of $117.1 million, with an additional $26.9 million net cash raised through ATM facility to date in the second quarter.
- Phase 3 program continuing in accordance with previously announced study design after FDA feedback received on the COMP 005 and COMP 006 trials.
Headline financials
Revenue & EPS history
COMPASS · Revenue · Quarterly
$0
Forward guidance
Second quarter 2023 net cash used in operating activities is expected to be in the range of $22 million to $30 million and the full-year 2023 to be in the range of $85 million to $110 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2023
-0.7%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.1%
Avg return
30 days after
32%
6 / 19 earnings
Positive
+25.1%
Q2 2022
Best reaction
-23.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -5.9% | +12.7% | +29.1% | |
| Q3 2025 | -0.5% | +4.7% | -12.3% | |
| Q1 2025 | +0.5% | +4.3% | +28.3% | |
| Q4 2024 | +5.9% | +4.1% | -20.5% | |
| Q3 2024 | -23.3% | -27.0% | -25.8% | |
| Q1 2024 | +0.0% | -4.9% | -18.7% | |
| Q4 2023 | -7.2% | -12.1% | -32.7% | |
| Q3 2023 | +10.9% | +4.7% | +5.5% | |
| Q2 2023 | -4.7% | -8.8% | +4.2% | |
| Q1 2023 | -4.1% | -2.3% | -8.7% | |
| Q4 2022 | -3.4% | +0.8% | +23.3% | |
| Q3 2022 | +2.0% | -3.9% | +14.4% | |
| Q2 2022 | +25.1% | +18.1% | +4.6% | |
| Q1 2022 | -8.2% | +3.7% | +33.0% | |
| Q4 2021 | +8.1% | +15.5% | -1.1% | |
| Q2 2021 | -5.8% | -8.1% | +5.4% | |
| Q4 2020 | -1.2% | +4.5% | -5.9% | |
| Q4 2019 | -1.2% | +4.5% | -5.9% | |
| Q3 2020 | -0.2% | +1.4% | +61.6% | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro